Plichta, Damian R.
Somani, Juhi
Pichaud, Matthieu
Wallace, Zachary S.
Fernandes, Ana D.
Perugino, Cory A.
Lähdesmäki, Harri
Stone, John H.
Vlamakis, Hera
Chung, Daniel C.
Khanna, Dinesh
Pillai, Shiv
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Funding for this research was provided by:
National Institutes of Health (U19 AI110495)
National Institutes of Health (UM1 AI144295, UM1-AI-110557, K24 AR063120)
Article History
Received: 24 July 2020
Accepted: 11 February 2021
First Online: 28 February 2021
Ethics approval and consent to participate
: Human patient research in the IgG4-RD cohort was reviewed and approved by the Partners Human Research Committee (2008P002154). Human patient research in the SSc cohort was approved by the Institutional Review Board of the University of Michigan Medical School (HUM00101836). Human patient research in the healthy control cohort was reviewed and approved by the Partners Human Research Committee (2015P000275). The study was approved by the Office of Research Subject Protection at the Broad Institute of MIT and Harvard. All experiments adhered to the regulations of these review boards. Study procedures were performed in compliance with all relevant ethical and federal regulations. This research conformed to the principles of the Helsinki Declaration. All study participants gave their written informed consent for sample collection and to participate in the study.
: Not applicable.
: RJX is a consultant to Novartis and Nestle. DK is a consultant to Acceleron, Actelion, Amgen, Bayer, Blade Therapeutics, Boehringer Ingelheim, CSL Behring, Corbus, Cytori, Galapagos, Genentech/Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Regeneron, Sanofi-Aventis, and United Therapeutics; CME programs: Impact PH; Stocks: Eicos Sciences, Inc.; Leadership/Equity position -Medical lead, Scleroderma Development, CiviBioPharma/Eicos Sciences, Inc. The remaining authors declare that they have no competing interests.